Table 1.
Median values and interquartile range (IQR) of TAbs-RBD (U/ml) and NAbs-RBD (%) SARS-CoV-2 spike antibodies after the first and second dose of BNT162b2 vaccine in the CF group (n = 33) and in the control group (n = 66).
| After 1st dose |
After 2nd dose |
||||
|---|---|---|---|---|---|
| TAbs-RBD (U/ml) | NAbs-RBD (%) | TAbs-RBD (U/ml) | NAbs-RBD (%) | ||
| Group | Cystic fibrosis n=33 |
222.45 (1162.05) |
79.60 (15.90) |
3396.00 (2443.00) |
97.30 (1.00) |
| Controls n=66 |
35.41 (105.75) |
57.63 (34.95) |
1452.00 (1231.00) |
95.70 (3.71) |
|
| P-value | <.001 | <.001 | <.001 | <.001 | |
Abbreviations: TAbs-RBD; Total antibodies against Receptor Binding Domain of SARS-CoV-2 spike protein, NAbs-RBD; Neutralizing antibodies (%). Values refer to median (interquartile range) and P-value of Mann-Whitney U test. Statistically significant values are marked in bold.